Effect of oral magnesium supplementation on cardio metabolic markers in people at risk of diabetes

Comparison of the effect of oral magnesium supplementation and placebo on cardio metabolic markers in prediabetes subjects: a randomized, double blinded clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181226042129N1

Enrollment

Registered

2019-04-01

Start date

2018-11-22

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes. Malnutrition-related diabetes mellitus

Interventions

Intervention 1: Intervention group: To these patients, oral magnesium tablets (320 mg) are given daily for a period of twelve weeks. The magnesium pill is the product of the Jalinus Pharmaceutical Com

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: prediabetes condition not consuming magnesium supplements in last 6 months and serum magnesium level less than 2mg/dL GFR > 60mL/min Blood pressure less than 140 / 90 mmHg

Exclusion criteria

Exclusion criteria: Pregnancy Chronic diseases Liver diseases Chronic diarrhea Smoking Consume diuretics Consuming anti hypertensive drugs

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: Day 0 and day 120. Method of measurement: Lab test.;HbA1c. Timepoint: Day 0 and 120. Method of measurement: Lab test.;Lipid profile. Timepoint: Day 0 and 120. Method of measurement: Lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolshan Taghipour Borujeni

Esfahan University of Medical Sciences

g.taghipour@resident.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026